U-Blot® Research Grade Tocilizumab
Ucallm.jpg
$9,999.00
Product details
Background：Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).
• Expression of Interleukin 6 signaling receptors in carotid atherosclerosis., PMID:33350884
• Preclinical development of CD126 CAR-T cells with broad antitumor activity., PMID:33414408
• Physiological effects of modulating the interleukin-6 axis., PMID:29982781
• Increased IL-6 and Potential IL-6 trans-signalling in the airways after an allergen challenge., PMID:33471392
• IL6 receptor inhibitors: exploring the therapeutic potential across multiple diseases through drug target Mendelian randomization., PMID:39229261
• Anti-Inflammatory Effect of Muscle-Derived Interleukin-6 and Its Involvement in Lipid Metabolism., PMID:34576053
• Identification of IL-6 Signalling Components as Predictors of Severity and Outcome in COVID-19., PMID:35634332
• M1-Like Macrophages Modulate Fibrosis and Inflammation of Orbital Fibroblasts in Graves’ Orbitopathy: Potential Relevance to Soluble Interleukin-6 Receptor., PMID:36617890
• The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes., PMID:31237452
• Soluble interleukin-6 receptor-mediated innate immune response to DNA and RNA viruses., PMID:23946454
Specifications
| Target | CD126 |
| Reactivity | Human |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| MW(Calculated) | |
| MW(Observed) | |
| Host Species | Humanized |
| Isotype | IgG1 |
| Conjugate/Modification | |
| Modification | |
| Recommended Dilution Ratio | |
| Composition | 0.01M PBS, pH 7.4. |
| Purification Process | Protein A/G purified from cell culture supernatant. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Storage Condition | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Concentration | |
| Clonality | Monoclonal |
| Clone Number | |
| Immunogen | Mammalian Cells |
| Gene Name | |
| Protein Name | |
| Alias | sIL6R, Interleukin-6 receptor subunit alpha, CD126, IL-6R 1, IL-6R subunit alpha, Membrane glycoprotein 80, gp80, IL6R, IL-6RA, IL-6 receptor subunit alpha, IL-6R-alpha |
| Species | |
| Gene ID-1 | P08887 |
| Uniprot | |
| Species.1 | |
| Gene ID | |
| Uniprot.1 | |
| Species.2 | |
| Gene ID.1 | |
| Uniprot.2 | |
| Organism-4 | |
| Gene ID-4 | |
| SwissProt-4 | |
| Description | Background：Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).<br>• Expression of Interleukin 6 signaling receptors in carotid atherosclerosis., PMID:33350884<br />• Preclinical development of CD126 CAR-T cells with broad antitumor activity., PMID:33414408<br />• Physiological effects of modulating the interleukin-6 axis., PMID:29982781<br />• Increased IL-6 and Potential IL-6 trans-signalling in the airways after an allergen challenge., PMID:33471392<br />• IL6 receptor inhibitors: exploring the therapeutic potential across multiple diseases through drug target Mendelian randomization., PMID:39229261<br />• Anti-Inflammatory Effect of Muscle-Derived Interleukin-6 and Its Involvement in Lipid Metabolism., PMID:34576053<br />• Identification of IL-6 Signalling Components as Predictors of Severity and Outcome in COVID-19., PMID:35634332<br />• M1-Like Macrophages Modulate Fibrosis and Inflammation of Orbital Fibroblasts in Graves' Orbitopathy: Potential Relevance to Soluble Interleukin-6 Receptor., PMID:36617890<br />• The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes., PMID:31237452<br />• Soluble interleukin-6 receptor-mediated innate immune response to DNA and RNA viruses., PMID:23946454<br /> |
| Cellular Localization | |
| Tissue Expression | |
| Signaling_pathway | |
| Research Areas | |
| Function |
Please login to post questions
Related products
